Ultragenyx Pharma (RARE) Misses Q4 EPS by 45c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/30/2026

1. NOW
2. GOOGL
3. MSFT
4. FTNT
5. EBAY
6. CMG
7. TENB
8. BIIB
9. KLAC
10. CART

Go back to Ultragenyx Pharma (RARE) Misses Q4 EPS by 45c

Ultragenyx Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update

February 10, 2022 4:05 PM EST

2021 total revenue of $351.4 million and 2021 Crysvita® revenue in Ultragenyx territories1 of $192.6 million

2022 Crysvita revenue in Ultragenyx territories guidance of $250 million to $260 million and Dojolvi revenue of $55 million to $65 million

Strong Dojolvi® launch continues with approximately 270 patients on reimbursed commercial therapy in the United States as of the end of 2021

Year-end 2021 cash balance of approximately $1.0 billion

NOVATO, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and... More